QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
NASDAQ:SLDB

Solid Biosciences (SLDB) Stock Forecast, Price & News

$0.55
-0.02 (-3.53%)
(As of 05/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.53
$0.58
50-Day Range
$0.43
$1.42
52-Week Range
$0.42
$4.92
Volume
334,632 shs
Average Volume
964,362 shs
Market Capitalization
$61.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.54
30 days | 90 days | 365 days | Advanced Chart
Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Solid Biosciences logo

About Solid Biosciences

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Headlines

Duchenne startup lays off 35% of staff, loses COO
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLDB
Fax
N/A
Employees
104
Year Founded
N/A

Sales & Book Value

Annual Sales
$13.62 million
Book Value
$1.89 per share

Profitability

Net Income
$-72.19 million
Net Margins
-660.25%
Pretax Margin
-660.25%

Debt

Price-To-Earnings

Miscellaneous

Free Float
84,722,000
Market Cap
$61.73 million
Optionable
Optionable

Company Calendar

Last Earnings
4/27/2022
Today
5/18/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.66 out of 5 stars

Medical Sector

69th out of 1,426 stocks

Biological Products, Except Diagnostic Industry

8th out of 210 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 1.3 5 -4 -3 -2 -1 -













Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

Is Solid Biosciences a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Solid Biosciences stock.
View analyst ratings for Solid Biosciences
or view top-rated stocks.

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Solid Biosciences
.

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) released its quarterly earnings data on Wednesday, April, 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.04. The business had revenue of $1.93 million for the quarter, compared to analyst estimates of $3.57 million. Solid Biosciences had a negative trailing twelve-month return on equity of 37.71% and a negative net margin of 660.25%. During the same period last year, the company earned ($0.19) EPS.
View Solid Biosciences' earnings history
.

What price target have analysts set for SLDB?

4 equities research analysts have issued 1-year target prices for Solid Biosciences' shares. Their forecasts range from $5.00 to $7.00. On average, they expect Solid Biosciences' stock price to reach $6.33 in the next twelve months. This suggests a possible upside of 1,057.4% from the stock's current price.
View analysts' price targets for Solid Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Solid Biosciences' key executives?
Solid Biosciences' management team includes the following people:
  • Mr. Ian F. Smith A.C.A., ACA, C.P.A., CPA, Exec. Chair (Age 56, Pay $72.73k)
  • Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 48, Pay $749.03k)
  • Mr. Matthew Bennett Arnold, Co-Founder & Board Member (Age 52, Pay $19.45k)
  • Dr. Joel Solomon Zev Schneider Ph.D., Chief Operating Officer (Age 37, Pay $547.71k)
  • Ms. Erin Powers Brennan, Chief Legal Officer & Sec. (Age 51, Pay $495.99k)
  • Mr. Gilad David Hayeem, Co-Founder (Age 54)
  • Ms. Annie Ganot, Co-Founder & Head of Patient Advocacy
  • Dr. Andrey Juan Zarur Ph.D., Co-Founder (Age 51)
  • Mr. Stephen J. DiPalma M.B.A., Interim CFO, Treasurer & Principal Accounting Officer (Age 63)
  • Dr. Carl Ashley Morris Ph.D., Chief Scientific Officer (Age 52) (LinkedIn Profile)
What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Cidara Therapeutics (CDTX), SCYNEXIS (SCYX), Verastem (VSTM) and Agile Therapeutics (AGRX).

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Suvretta Capital Management LLC (6.40%), BlackRock Inc. (5.16%), Vanguard Group Inc. (1.88%), Alyeska Investment Group L.P. (1.17%), Renaissance Technologies LLC (1.12%) and State Street Corp (0.95%). Company insiders that own Solid Biosciences stock include Carl Ashley Morris, Ilan Ganot, Jennifer Lynn Ziolkowski, Joel Solomon Zev Schneider, Perceptive Advisors Llc and Ra Capital Management, LP.
View institutional ownership trends for Solid Biosciences
.

Which major investors are selling Solid Biosciences stock?

SLDB stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Goldman Sachs Group Inc., Connor Clark & Lunn Investment Management Ltd., JPMorgan Chase & Co., Northern Trust Corp, Charles Schwab Investment Management Inc., and Simplex Trading LLC. Company insiders that have sold Solid Biosciences company stock in the last year include Carl Ashley Morris, Ilan Ganot, and Joel Solomon Zev Schneider.
View insider buying and selling activity for Solid Biosciences
or view top insider-selling stocks.

Which major investors are buying Solid Biosciences stock?

SLDB stock was bought by a variety of institutional investors in the last quarter, including Suvretta Capital Management LLC, Renaissance Technologies LLC, Alyeska Investment Group L.P., XTX Topco Ltd, State Street Corp, Mirabella Financial Services LLP, and Russell Investments Group Ltd.. Company insiders that have bought Solid Biosciences stock in the last two years include Perceptive Advisors Llc, and Ra Capital Management, LP.
View insider buying and selling activity for Solid Biosciences
or or view top insider-buying stocks.

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $0.55.

How much money does Solid Biosciences make?

Solid Biosciences has a market capitalization of $61.73 million and generates $13.62 million in revenue each year. The company earns $-72.19 million in net income (profit) each year or ($0.72) on an earnings per share basis.

How many employees does Solid Biosciences have?

Solid Biosciences employs 104 workers across the globe.

What is Solid Biosciences' official website?

The official website for Solid Biosciences is www.solidbio.com.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 337-4680.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.